TORONTO, Ontario, June 23, 2021 – Awakn Life Sciences Corp. (“Awakn” or the “Company”) a biotechnology company with clinical operations developing, and delivering psychedelic medicines to treat Addiction, is pleased to announce it will begin trading today, June 23, 2021, on the NEO Exchange Inc. (the “NEO”) under the symbol “AWKN”. “Listing on the NEO is an important milestone for Awakn to…

Source

Previous articleMYND Life Sciences Expands Intellectual Portfolio to Target Alzheimer’s disease and related forms of Dementia with Chemical Subclasses of Psilocybin Analogues
Next articleMindMed Appoints MGH Psychiatrist-in-Chief Dr. Maurizio Fava to Scientific Advisory Board